Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 552

1.

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.

Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF.

J Clin Oncol. 2010 Apr 20;28(12):2051-7. doi: 10.1200/JCO.2009.26.5520. Epub 2010 Mar 22. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543.

PMID:
20308655
2.

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.

Perry JR, Rizek P, Cashman R, Morrison M, Morrison T.

Cancer. 2008 Oct 15;113(8):2152-7. doi: 10.1002/cncr.23813.

3.

Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role?

Wen PY.

J Clin Oncol. 2010 Apr 20;28(12):1977-9. doi: 10.1200/JCO.2009.27.6014. Epub 2010 Mar 22. No abstract available.

PMID:
20308652
4.

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.

Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M.

J Clin Oncol. 2009 Dec 10;27(35):5874-80. doi: 10.1200/JCO.2009.23.6497. Epub 2009 Nov 9. Erratum in: J Clin Oncol. 2010 Feb 1;28(4):708.

PMID:
19901110
5.
6.

Rechallenge with temozolomide in patients with recurrent gliomas.

Wick A, Pascher C, Wick W, Jauch T, Weller M, Bogdahn U, Hau P.

J Neurol. 2009 May;256(5):734-41. doi: 10.1007/s00415-009-5006-9. Epub 2009 Feb 25.

PMID:
19240962
7.

Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.

Lanzetta G, Campanella C, Rozzi A, Nappa M, Costa A, Fedele F, Innocenzi G, Gagliardi FM, Salvati M, Minniti G, Frati A, Frati L, Vecchione A.

Anticancer Res. 2003 Nov-Dec;23(6D):5159-64.

PMID:
14981983
8.

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.

Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, Abrey LE.

J Clin Oncol. 2009 Aug 10;27(23):3861-7. doi: 10.1200/JCO.2008.20.7944. Epub 2009 Jun 8.

9.

Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.

Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, Antonadou D, Saris G, Beroukas K, Karageorgis P.

J Clin Oncol. 2005 Apr 1;23(10):2372-7.

PMID:
15800329
10.

Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients.

Wang Y, Kong X, Guo Y, Wang R, Ma W.

Medicine (Baltimore). 2017 Mar;96(10):e6261. doi: 10.1097/MD.0000000000006261.

11.

Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.

Minniti G, Scaringi C, De Sanctis V, Lanzetta G, Falco T, Di Stefano D, Esposito V, Enrici RM.

J Neurooncol. 2013 Jan;111(2):187-94. doi: 10.1007/s11060-012-0999-9. Epub 2012 Nov 6.

PMID:
23129347
12.

Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.

Iuchi T, Hatano K, Kodama T, Sakaida T, Yokoi S, Kawasaki K, Hasegawa Y, Hara R.

Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):793-800. doi: 10.1016/j.ijrobp.2013.12.011. Epub 2014 Feb 1.

PMID:
24495592
13.

Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.

Kong DS, Lee JI, Kim JH, Kim ST, Kim WS, Suh YL, Dong SM, Nam DH.

Neuro Oncol. 2010 Mar;12(3):289-96. doi: 10.1093/neuonc/nop030. Epub 2010 Jan 11.

14.

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.

Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO, Leyvraz S.

J Clin Oncol. 2002 Mar 1;20(5):1375-82.

PMID:
11870182
15.

Temozolomide in paediatric high-grade glioma: a key for combination therapy?

Verschuur AC, Grill J, Lelouch-Tubiana A, Couanet D, Kalifa C, Vassal G.

Br J Cancer. 2004 Aug 2;91(3):425-9.

16.

Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.

Silvani A, Eoli M, Salmaggi A, Lamperti E, Maccagnano E, Broggi G, Boiardi A.

J Neurooncol. 2004 Jan;66(1-2):203-8.

PMID:
15015788
17.

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.

Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M.

J Clin Oncol. 2008 May 1;26(13):2192-7. doi: 10.1200/JCO.2007.14.8163.

PMID:
18445844
18.

Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.

Gerstein J, Franz K, Steinbach JP, Seifert V, Rödel C, Weiss C.

Strahlenther Onkol. 2011 Nov;187(11):722-8. doi: 10.1007/s00066-011-2230-x. Epub 2011 Oct 28.

PMID:
22037649
19.

First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.

Bock HC, Puchner MJ, Lohmann F, Schütze M, Koll S, Ketter R, Buchalla R, Rainov N, Kantelhardt SR, Rohde V, Giese A.

Neurosurg Rev. 2010 Oct;33(4):441-9. doi: 10.1007/s10143-010-0280-7. Epub 2010 Aug 13.

20.

Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.

Groves MD, Puduvalli VK, Gilbert MR, Levin VA, Conrad CA, Liu VH, Hunter K, Meyers C, Hess KR, Alfred Yung WK.

Br J Cancer. 2009 Aug 18;101(4):615-20. doi: 10.1038/sj.bjc.6605189.

Supplemental Content

Support Center